Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of the Utility of Family-based (Trio) Whole-genome Sequencing for Cancer Predisposition Testing in Sequential Newly Diagnosed Paediatric and Adolescent Cancer Patients

NCT04903782 is registered in ClinicalTrials.gov with Sydney Children's Hospitals Network as lead sponsor.

NCT NCT04903782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04903782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of the Utility of Family-based (Trio) Whole-genome Sequencing for Cancer Predisposition Testing in Sequential Newly Diagnosed Paediatric and Adolescent Cancer Patients
Lead sponsor
Sydney Children's Hospitals Network
Phase
Observational
Overall status
Recruiting
Start date
March 8, 2021
Completion date
June 15, 2028
Enrollment
270 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, genetic predisposition to disease, neoplastic syndromes, hereditary